[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solitary-pulmonary-nodule\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solitary-pulmonary-nodule":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100651962","multiparametric-lung-mri-with-diffusion-weighted-imaging-in-lung-rads-4-lesion-characterization-100651962",false,"NCT07768046","Multiparametric Lung MRI With Diffusion-Weighted Imaging in Lung-RADS 4 Lesion Characterization","Multiparametric Lung MRI With Diffusion-Weighted Imaging in Lung-RADS 4 Lesion Characterization: A Single-Center Prospective Diagnostic Accuracy Study","Inclusion Criteria:\n\n1. Age 50 to 80 years, inclusive.\n2. At least a 20 pack-year cigarette smoking history, and currently smoking or quit within the past 15 years (2021 USPSTF lung cancer screening eligibility).\n3. Underwent a standard-of-care lung cancer screening low-dose chest CT (LDCT) at the University of Florida that was assigned Lung-RADS category 4 (4A, 4B, or 4X) per ACR Lung-RADS v2022.\n4. Able to provide written informed consent independently.\n\nExclusion Criteria:\n\n1. Part-solid or cystic nodule with a solid component measuring less than 8 mm.\n2. Endobronchial nodule.\n3. MRI-incompatible or potentially MRI-incompatible implanted device.\n4. Claustrophobia that would prevent the participant from tolerating the MRI examination.\n5. Metallic device in the chest wall or spine that may interfere with adequate image acquisition in the field of view (assessed case by case).\n6. History of prior lung resection for a benign condition that may create susceptibility artifact in the field of view.\n7. Home oxygen supplementation.\n8. Active or treated lower respiratory tract infection within the prior 4 weeks.\n9. Lack of capacity to consent.","ALL","50 Years","80 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","This study evaluates whether multiparametric chest magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI), performed without any contrast material, can distinguish malignant from benign lung lesions that were assigned Lung-RADS category 4 on a standard-of-care lung cancer screening low-dose CT.\n\nParticipants who have a Lung-RADS 4 lesion on screening CT undergo one non-contrast research MRI of the chest at 3.0 Tesla. The MRI is added to standard care; no standard-of-care imaging, biopsy, or treatment is withheld or replaced, and the research MRI is not used for clinical decision making. Participants then continue routine clinical management, and the final nature of the lesion is established from pathology or microbiology when tissue is obtained, or otherwise from at least 24 months of clinical and imaging follow-up.\n\nThe primary measure is the sensitivity and specificity of multiparametric MRI against that final diagnosis. Secondary measures include whether DWI alone performs as well as the full MRI protocol, how MRI compares with PET\u002FCT in participants who had PET\u002FCT as part of their care, and quantitative MRI thresholds (apparent diffusion coefficient, lesion-to-spinal-cord signal intensity ratio, native T1 and T2).\n\nThis is an exploratory pilot and feasibility study. No formal power calculation was performed; the sample size is intended to support feasibility assessment, protocol optimization, and preliminary estimates of diagnostic performance.",[25,26,27,28],"Solitary Pulmonary Nodule","Multiple Pulmonary Nodules","Lung Neoplasms","Lung Cancer Screening",[30,31,32,33,34,35,36,37,38],"Lung-RADS 4","diffusion-weighted imaging","apparent diffusion coefficient","multiparametric MRI","lung cancer screening","low-dose CT","pulmonary nodule","diagnostic accuracy","non-contrast MRI","NOT_YET_RECRUITING","2026-08-17",{"date":42,"type":43},"2026-08-19","ACTUAL",{"date":45,"type":21},"2027-01",{"date":47,"type":21},"2032-01",{"name":49,"class":50},"University of Florida","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100573096","confocal-laser-endomicroscopy-guided-cryobiopsy-in-the-diagnosis-of-interstitial-lung-disease-100573096","NCT06741826","Confocal Laser Endomicroscopy Guided Cryobiopsy in the Diagnosis of Interstitial Lung Disease","The Diagnostic Performance and Safety of Confocal Laser Endomicroscopy Guided Transbronchial Lung Cryobiopsy in the Diagnosis of Interstitial Lung Disease: a Randomised Controlled Trial","Inclusion Criteria:\n\n* Patients with peripheral pulmonary nodules suspected of lung cancer by CT examination\n* Patients who intend to undergo a bronchoscopic lung biopsy to determine benign or malignant pulmonary nodules;\n* Age ≥18 years\n* Sign informed consent.\n\nExclusion Criteria:\n\n* There is an uncorrectable coagulation disorder or anticoagulation therapy that cannot be stopped before surgery;\n* Tumors can be seen in the bronchus\n* Hemodynamic instability;\n* Refractory hypoxemia;\n* Patients with pregnant and lactating patients\n* Any illness or condition that interferes with the completion of the initial or subsequent assessment.","18 Years",{"count":61,"type":21},530,"INTERVENTIONAL",[64],"NA","A prospective multicenter randomized controlled trial was conducted to evaluate the diagnostic efficacy and safety of NCLE-NB-Rebus-guided peripheral pulmonary nodule biopsy, and to compare the diagnostic efficacy and safety of biopsy forceps biopsy and needle aspiration biopsy in peripheral pulmonary nodule biopsy guided by nCLE-NB-rEBUS.",[25,67],"Multiple Pulmonary Nodule","2024-12-16",{"date":70,"type":43},"2024-12-19",{"date":72,"type":21},"2025-01-01",{"date":74,"type":21},"2026-12-31",{"name":76,"class":50},"China-Japan Friendship Hospital",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":62,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100409720","phase-3-18f-2-fluoro-2-deoxy-d-glucose-in-positron-emission-tomography-computed-tomography-100409720","NCT04615156","18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography","Evaluation of 18F-2-fluoro-2-deoxy-D-glucose Produced by a New Manufacturer, for Safety, Through the Identification of Adverse Events, and Efficacy, Through the Evaluation of Its Ability, When Utilized in Performance of a Positron Emission Tomography Computed Tomography Scan, to Correctly Distinguish Benign From Malignant Solitary Pulmonary Nodules.","Inclusion Criteria:\n\n* Known or suspected disease for which 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography Computed Tomography is appropriate for the investigation of. This includes, but is not limited to: Known or suspected cancer, neurological disorders (dementia or epilepsy), cardiac conditions (inflammation or myocardial viability), known or suspected presence of infection\u002Finflammation process\n\nPatients must satisfy all the following:\n\n* Able to provide written informed consent, or consent obtained from appropriate guardian\n* Able to tolerate the physical and logistic requirements of completing a Positron Emission Tomography Computed Tomography scan\n\nExclusion Criteria:\n\n* Pregnant women: if there is any possibility of pregnancy, a blood Beta Human Chorionic Gonadotropin level will be obtained as per Eastern Health policy.\n* Patients unwilling or unable to stop breast feeding for 12 hours\n* Patients who are too medically unstable to tolerate the uptake period or lie flat for the duration of the scan\n* Patients who exceed the safe weight limit of the Positron Emission Tomography Computed Tomography scanner bed (500 lbs.) or who cannot fit through the bore (70 cm diameter)\n* Patients unwilling to proceed with scan (I.e. claustrophobia) prior to injection\n* If patients inability to follow staff direction causes a safety hazard prior to injection",{"count":85,"type":21},10000,[87],"PHASE3","The study objectives are as follows:\n\n* To determine the safety of trial 18F-2-fluoro-2-deoxy-D-glucose, produced by a new manufacturer, by surveillance for adverse events in patients having Positron Emission Tomography Computed Tomography scans in a comprehensive program for indications including, but not limited to, oncology, neurology, cardiac and infectious\u002Finflammatory processes.\n* To determine the efficacy of 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography in differentiating benign from malignant solitary pulmonary nodules and calculate sensitivity, specificity, and accuracy using pathologic confirmation as the gold standard when available, or greater than 6 month follow up stability on Computed Tomography scan when not.\n\nThe purpose of performing this clinical trial is to provide local access of 18F-2-fluoro-2-deoxy-D-glucose to the patients of Newfoundland and Labrador. This product has been offered to patients over the last three years by transporting from facilities outside of the province. There have been significant delays in access and in fact, times where 18F-2-fluoro-2-deoxy-D-glucose has not been available through this process. This has caused delays and limitations of treatments for patients who rely on Positron Emission Tomography Computed Tomography scans for diagnosis.",[25,90,91,92],"Oncology","18F-2-fluoro-2-deoxy-D-glucose","Adverse Event",[91,92,25,90],"2020-11-02",{"date":96,"type":43},"2020-11-04",{"date":98,"type":21},"2020-11-01",{"date":100,"type":21},"2027-11-01",{"name":102,"class":50},"Eastern Health, Canada"]